Amylyx Pharmaceuticals, Inc. (AMLX)
NASDAQ: AMLX · Real-Time Price · USD
14.30
+0.78 (5.77%)
At close: Jan 16, 2026, 4:00 PM EST
14.40
+0.10 (0.72%)
After-hours: Jan 16, 2026, 7:52 PM EST
Amylyx Pharmaceuticals Revenue
Amylyx Pharmaceuticals had revenue of $-665.00K in the twelve months ending September 30, 2025. In the year 2024, Amylyx Pharmaceuticals had annual revenue of $87.37M, down -77.06%.
Revenue (ttm)
$-665.00K
Revenue Growth
-77.06%
P/S Ratio
-2,361.53
Revenue / Employee
n/a
Employees
123
Market Cap
1.57B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 87.37M | -293.42M | -77.06% |
| Dec 31, 2023 | 380.79M | 358.56M | 1,612.94% |
| Dec 31, 2022 | 22.23M | 21.95M | 7,700.00% |
| Dec 31, 2021 | 285.00K | -365.00K | -56.15% |
| Dec 31, 2020 | 650.00K | -776.00K | -54.42% |
| Dec 31, 2019 | 1.43M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
AMLX News
- 9 days ago - Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra A/S - Business Wire
- 6 weeks ago - Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial - Business Wire
- 6 weeks ago - Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 7 weeks ago - HALPER SADEH LLC ENCOURAGES AMYLYX PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS - PRNewsWire
- 2 months ago - Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Amylyx Pharmaceuticals, Inc. – AMLX - Business Wire
- 2 months ago - Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Amylyx Pharmaceuticals Reports Third Quarter 2025 Financial Results - Business Wire
- 2 months ago - Amylyx Pharmaceuticals to Present at Upcoming Investor Conferences - Business Wire